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Overview of Diuretic Strategies in Edematous States
Kedar Mahajan, MD

Introduction
Considering potential physiologic causes of volume overload in
clinical practice, such as heart failure, renal failure, nephrotic
syndrome, or portal hypertension, may yield insight into
directing therapy beyond switching from oral to intravenous
diuretic therapy. Appropriate oral therapies that achieve effective
diuresis may reduce costs, address shortages of intravenous loop
diuretics, reduce the need for unnecessary inpatient admissions
by facilitating outpatient management, allow earlier optimization
of outpatient regimens, and decrease the length of hospital stay.

Congestive Heart Failure
Decreased responsiveness to oral diuretics in either high or
low output heart failure has been described. Goldman’s Cecil
Medicine identifies factors such as gut edema, hypotension,
reduced renal blood flow, and adaptive changes in the nephron.1
Bowel wall edema from elevated systemic venous pressures in
heart failure may decrease bioavailability of diuretics while
increased renal afterload from venous congestion and intrinsic
renal compromise from interstitial pressures impairs diuresis.2
“Adaptive changes” are seen in long term loop diuretic use and
include hypertrophy and hyperplasia of the distal convoluted
tubule cells and increased Na+/Cl- - cotransporter activity
which both contribute to increased sodium reabsorption.3 This
adaption is partially addressed by blocking the reabsorption with
thiazide/thiazide-like (e.g. hydrochlorothiazide or metolazone)
diuretics and decreasing Na+/Cl- - cotransporter upregulation
by inhibiting effects of aldosterone (e.g. spironolactone or
eplerenone). 1, 3
Optimal outpatient management of diuresis in heart failure is
often difficult. Doubling the oral dose of diuretics (furosemide,
torsemide, and metolazone) does not affect left ventricular
systolic or diastolic function, has been shown to improve
symptoms and 6-minute walk distance after a 24 day endpoint.4
Detrimental effects of high-dose diuretics in systolic dysfunction
have be associated with increased mortality raising controversy,
but confounding factors such as diuretic resistance or heart
failure severity have made these links uncertain.5 The superior
pharmacodynamic profile of toresemide (see Table 1) and its
anti-aldosterone and vasorelaxation effect likely contributes to
its better performance in improving left ventricular function,
reduction of mortality, frequency/duration of heart-failure
related hospitalization, quality of life, exercise tolerance and
New York Heart Association functional class compared with
furosemide.6, 7 Synergy of loop-diuretics with potassium sparing
or thiazide diuretics is efficacious in persistent edematous states.8
Additionally, inadequate tissue perfusion, signaled by increasing
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blood urea nitrogen or serum creatinine, can be addressed
during diuresis in heart failure with inotropes or vasodilators.

Renal Disease
Patients with renal insufficiency benefit from loop diuretics
since they retain their utility at a creatinine clearance (CrCl) < 5
mL/min while distal tubule diuretics lose their efficacy at a CrCl
< 40 mL/min. However, thiazides and thiazide-like diuretics
(e.g. metolazone), provide synergistic effects when administered
thirty min prior to a loop diuretic to inhibit compensatory distal
tubular reabsorption, which avoids having to increase loop
dosages and limits long-term exposure to high-dose diuretics.9, 10
Higher doses of diuretics are required with a fall in the glomerular
filtration rate, whether in chronic kidney disease (CKD), acute
kidney injury, or hypoperfusion states. Drug secretion into the
lumen of the nephron is diminished with retention of competing
anions in renal failure and fewer functioning nephrons limit the
maximal response of the drug. Moderate CKD can require 80 mg
of intravenous furosemide (or bumetanide 2-3 mg, or torsemide
20-50 mg) while 200 mg may be required with severe CKD (or
bumetanide 8-10 mg, or torsemide 50-100 mg).11
Renal tubular secretion of furosemide is typically normal in
nephrotic syndrome but since the diuretic is bound to urinary
albumin, the lack of active drug blunts the diuretic response. If
urinary albumin exceeds 4 g/L, 50-66% of the drug is bound to
albumin and inactive.12 Appropriate measures include increasing
doses, frequency, and using thiazides in conjunction with
loop-diuretics. Avoidance of renal vasoconstriction mediated by
non-steroidal anti-inflammatory drugs (NSAIDs) also improves
diuretic responsiveness.

Portal Hypertension
Limited cardiac output in heart failure decreases loop diuretic
secretion into the tubular lumen from decreased renal perfusion,
while cirrhosis through renal vasoconstriction. The mainstay
diuretic in managing moderate-volume ascites in cirrhosis is
either spironolactone (50-200 mg/day) or amiloride (5-10 mg/
day) with low doses of furosemide (20-40 mg day) to supplement
natriuresis if peripheral edema is present. The recommended
daily weight loss in these patients without and with peripheral
edema is up to 1 lb and 2 lbs respectively to prevent pre-renal
failure. 13 Patients with large-volume ascites and marked
abdominal discomfort impairing activities of daily living can
ideally undergo therapeutic paracentesis or attempt maximum
doses of spironolactone (400 mg/day) and furosemide (160
mg/day). These patients typically present with urinary sodium
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Table 1. Pharmacodynamics and kinetics of common diuretics
Onset (min)
Furosemide (PO)

30 – 60

Furosemide (IV)

5

Peak (hours)
1–2

Duration (hours)
6–8

τ½ (hours)

Bioavailability (%)

0.5 – 2*

47 – 64

2

Bumetanide (PO)

10

1

4–6

1 – 1.5

59 – 89

Torsemide (PO)

60

1–2

6–8

3.5†

80

Ethacrynic acid (PO)

30

2

12

2–4

Metolazone (PO)

60

≥ 24

20

48-72

1.3‡

Spironolactone (PO)

3–4

* End-stage renal disease: half-life (τ½) increases to 9 hours
† Cirrhosis: half-life (τ½) increases to 7-8 hours
‡ Active metabolites have the following half-lives (τ½): canrenone: 10-23 hours; 7-alpha-spirolactone: 7-20 hours
Loop diuretic equivalency: furosemide 40 mg PO = furosemide 20 mg IV = bumetanide 1 mg PO/IV = torsemide 20 mg PO/IV = ethacrynic acid 50 mg PO
(sulfonamide alternative)
(Adapted from Lexi-Comp)

< 10 mM and normal free-water excretion and serum sodium.
When free-water excretion is impaired, dilutional hyponatremia
develops spontaneously or with increased fluid intake.
Patients with anasarca can have 2-3 L of fluid removed daily
without reduction in plasma volume whereas patients with
isolated ascites (no peripheral edema), can only have 300-500
mL/day of ascitic fluid mobilized daily without risking
azotemia.14 The azotemia will improve after ceasing diuresis and
fluid repletion whereas hepatorenal syndrome, often mistakenly
linked to diuretic use, will continue to worsen. Similar to patients
in acute or chronic heart failure, rapid diuresis in cirrhotic
patients leads to decreased cardiac output. Diuretic-resistant
ascites is defined by either inability to mobilize ascites despite
sodium restriction (24-hour urine with < 78 mEq sodium or a
random urine sodium < urine potassium) and maximum oral
diuretics (spironolactone 400 mg/day and furosemide 160 mg/
day) or prohibitive diuretic-related complications (progressive
azotemia, hepatic encephalopathy, or progressive electrolyte
imbalance) in the absence of NSAIDs.15 Ceasing beta-blockers,
angiotensin receptor blockers, or angiotensin converting enzyme
inhibitors, can improve blood pressure, tissue perfusion, renal
function, and diuretic responsiveness.

Discussion
Compounding renal insufficiency with reduced intestinal
motility, perfusion, mucosal edema and tolerance to oral
diuretics may also project a need for intravenous therapy;
however, awareness of the pharmacokinetics and dynamics of
diuretics will often provide solutions.16 All diuretics need to
attain a minimal rate of tubular excretion before a response is
attained. Minimal response at a given dose indicates the dose
was effective in achieving the minimal rate but the effect was
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short-lived; a twice daily regimen can achieve the desired urine
output. However, no response following a diuretic suggests
doubling the dose (maximum furosemide dose 320-400 mg PO
or 160-320 mg IV) for diuresis.11 Between the minimum drug
excretion rate required for initiating diuresis and a plateau where
further drug excretion does not produce additional output, lies
the critical curve where drug excretion correlates to the extent
of naturesis.
Tolerance exists even with consecutive multiple intravenous doses
of furosemide in healthy individuals where naturesis/diuresis
decreases with compensatory increased renin and decreased
atrial natriuretic peptide.17 Outpatient diuretic tolerance can
be compounded by renal compensatory mechanisms or an
impaired natriuretic response to furosemide if on a low sodium
diet. 18 A few weeks of a diuretic dose will activate sodium
retaining forces (e.g. renin-angiotensin II-aldosterone, norepinephrine, or reduction in system blood pressure) to achieve
steady-state in sodium intake and excretion.19 However, poor
adherence to sodium restriction on the other hand will prevent
net fluid loss despite adequate diuresis; greater than 100 mEq
sodium (2 g sodium = 88 mEq) in a 24-hour urine collection
suggests non-compliance.20
Approaches that use higher doses of the drug, increased
frequency, or synergy with other diuretics are required to
overcome sodium retention. Substantial responses in diuretic
naïve patients are likely due to a lack of these adaptations. Acute
decompensated patients on outpatient doses of furosemide doses
≥ 120 mg/day benefit from initial bolus doses inpatient while
outpatient regimens with lower doses responded better to initial
continuous dosing.21 Other loop diuretics such as bumetanide
and toresemide boast of superior bioavailability (Table 1) and
can be considered first-line agents over furosemide in certain
cases. In heart failure patients, toresemide has been shown to
decrease left-ventricular remodeling, rates of hospitalization,
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and mortality over furosemide.6 When compared to furosemide,
bumetanide was more effective in reducing edema in patients
with nephrotic syndrome and dyspnea in heart failure.6 Certain
localized edematous states secondary to venous insufficiency,
moderate-severe lymphedema, or malignant ascites require
caution against depleting plasma volume when using diuretics.14
Given the multifactorial causes of diuresis failure, exploring the
nature of the edema state, utilizing a different diuretic agent or
considering an additional agent, changing the route, frequency
(Table 1), or the dose, can be attempted. The bioavailability of
a diuretic will influence the dose required for a response while
the plasma half-life will determine frequency of administration.
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